Enzo Biochem Inc. (ENZ) Reaches New 12-Month High at $6.85
Shares of Enzo Biochem Inc. (NYSE:ENZ) reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $6.85 and last traded at $6.65, with a volume of 298,081 shares traded. The stock had previously closed at $6.50.
Separately, Zacks Investment Research upgraded shares of Enzo Biochem from a “hold” rating to a “buy” rating and set a $6.25 price target on the stock in a research report on Thursday, June 16th.
The company has a market cap of $302.10 million and a P/E ratio of 17.09. The stock has a 50 day moving average of $5.98 and a 200-day moving average of $5.09.
Enzo Biochem (NYSE:ENZ) last issued its earnings results on Wednesday, June 8th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.02. The firm earned $18.16 million during the quarter, compared to analysts’ expectations of $24.50 million. During the same period in the prior year, the company earned ($0.07) EPS. Equities research analysts predict that Enzo Biochem Inc. will post ($0.23) earnings per share for the current fiscal year.
Enzo Biochem, Inc (Enzo) is an integrated life science and biotechnology company, which is engaged in the research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.